Award Data

DESCRIPTION (provided by applicant): We will develop an instrument to improve the healthcare of the most frail members of the elderly community. This population; elderly or recovering patients living at home or in an extended care facility is too frail toleave this environment and, as such, is subject to significantly reduced physical activity. Although numerous studies have confirmed that contin ...

DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for treatment of autoimmune diseases and organ transplantation. However, development of ?CD154 as a therapeutic has been impeded by antibody toxicity observed in early clinical trials. With nearly 50 mill ...

DESCRIPTION (provided by applicant): The evaluation and selection of safe and effective pharmacotherapies for drug abuse and addiction is performed through clinical trials that rely on patients taking the studied medication at the specified time and frequency. To ensure accurate efficacy measures, adherence to the prescribed regimen must be known. Creare proposes to develop an adherence monitoring ...

DESCRIPTION (provided by applicant): Research at the intersection of limnology and public health is showing that toxins produced from cyanobacteria act as an environmental trigger for Amyotrophic Lateral Sclerosis (ALS) commonly known as Lou Gehrig's Disease. Additional linkages are being made between cyanobacteria and Parkinson's and several acute illnesses and neurological disorders. A ...

DESCRIPTION (provided by applicant): New clinical guidelines for the treatment of exacerbations in cystic fibrosis (CF) were recently published by the American Thoracic Society. Examples of these evidence-based recommendations include not performing synergy testing to combat multi-drug-resistant infections, and using only one daily dose of aminoglycoside antibiotics, which was found equally effect ...

DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is the leading cause of death in the world. The staggering mortality rate is expected to increase significantly in the next ten years. In the U.S., an estimated 81 million adults will haveone or more types of cardiovascular disease with an estimated total annual direct and indirect economic burden of 400 billion. Atherosclerosis i ...

DESCRIPTION (provided by applicant): Assessment of lung function in neonates and infants Lung disease is the most common chronic disease of childhood, but methods for assessing lung disease such as spirometry cannot be performed by young children. Thus clinicians have only parental reports of patient symptoms upon which to base treatment decisions. Further, clinical trials of treatments for lung d ...

DESCRIPTION (provided by applicant): While large, prospective, blinded trials are the gold standard in clinical research, they require significant commitments of resources and time. Further, since these trials seek the answer to rather specific questions,the applicability and scalability of data obtained in these large trials is limited by the way in which it was collected. These trials will like ...

DESCRIPTION (provided by applicant): Roughly one million Americans with inadequately controlled severe persistent asthma have a particularly high risk of exacerbations, hospitalizations, and death, and account for a per-patient health care burden exceeding12,000 annually. Bronchial thermoplasty (BT) applies radiofrequency heating to airway smooth muscle reducing its thickness and hyper-reactivity. ...

This technology introduces a new non-invasive, biopsy-adjunct with a MNP platform for targeted tumor delivery. It employs closely sized magnetic nanoparticles (CS-MNP's) for determining their concentration and spatial distribution in tumor vasculatures asmeasured by magnetic resonance imaging (MRI). The relationship between CS-MNP size and Vibrating Sample Magnetometer (VSM) measurement foll ...